drugset / Trial / NCT03945175

Study of the Duration and Efficacy of MYDAYIS on Adult ADHD Symptoms and Executive Function Throughout the Day Into the Early Evening

NCT03945175 ↗

Phase 3 Completed 52 enrolled NYU Langone Health
NaSingle-groupOpen-labelTreatment

Summary

Attention-deficit/hyperactivity disorder (ADHD) is a neuropsychiatric disorder characterized by problems with sustaining attention, organization, planning, procrastination, daydreaming, restlessness, impulsivity and hyperactivity.This is an outpatient study for subjects between the ages of 18-60, who have an Attention deficit hyperactivity disorder (ADHD) diagnosis meeting all inclusion criteria and not meeting any of the exclusion criteria.

Timeline

Start
2020-07-15
Primary completion
2022-05-11
Completion
2022-05-11

Drugs

EvaluationDrugModalityDoseRoute
Subject MYDAYIS Unknown 12.5 mg —
Subject MYDAYIS Unknown 25 mg —
Subject MYDAYIS Unknown 37.5 mg —